MedTrace Logo

ADEQUATE Advanced Diagnostics for Enhanced Quality of Antibiotic Prescription

NCT04547556 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2024-10-15

Study results available
· View outcomes & findings →

Summary

To assess the impact of rapid diagnostic testing of patients with Acute Respiratory Tract Infection (ARTI) at the emergency department, on (1) hospital admission rates and (2) antimicrobial prescriptions (days of treatment) and (3) the non-inferiority in terms of clinical outcome. Geographical and seasonal variation will be assessed on a real time basis including pathogens of public health interest. The impact will be stratified within age groups and risk factors in order to determine the long-term clinical, public health and economic determinants for the integration of diagnostics in a global and sustainable perspective.

Conditions

  • Respiratory Tract Infections

Interventions

DIAGNOSTIC_TEST

BioFire

A molecular rapid syndromic testing platform, using the following panels: * BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus) * BioFire FilmArray Pneumonia Panel plus (PP)

Sponsors & Collaborators

  • BioMérieux

    collaborator INDUSTRY

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Marc Bonten, MD · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-25
Primary Completion
2022-05-21
Completion
2022-05-21
FDA Device
Yes

Countries

  • Belgium
  • Hungary
  • Serbia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04547556 on ClinicalTrials.gov